New therapeutic entities: The rise of the supergenerics

Innovative research-based pharmaceutical industries are indisputably clever creatures. They seek intellectual property protection for each of their new molecules and, where possible, for the overall drug products. In particular they use patents, not only as a strategy for becoming the sole marketer and enjoying significant financial returns along the way, but also for driving away competitors.